Ryan Ellis

Dr. Ryan Ellis

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2022 in Cancers
Verified
Journal Article
Open access
PDF file
RERyan Ellis
Ryan Ellis
SKSoares Kevin
Soares Kevin
WJWilliam R. R Jarnagin
William R. R Jarnagin
Perihilar cholangiocarcinoma is a rare hepatobiliary malignancy that requires thoughtful, multidisciplinary evaluation in the preoperative setting to ensure optimal patient outcomes. Comprehensive preoperative imaging, including multiphase CT angiography and some form of cholangiographic assessment, is key to assessing resectability. While many staging systems exist, the Blumgart staging system provides the most useful combination of resectability assessment and prognostic information for use in the preoperative setting. Once resectability is confirmed, volumetric analysis should be performed. Upfront resection without biliary drainage or portal venous embolization may be considered in patients without cholangitis and an estimated functional liver remnant (FLR) > 40%. In patients with FLR < 40%, judicious use of biliary drainage is advised, with the goal of selective biliary drainage of the functional liver remnant. Percutaneous biliary drainage may avoid inadvertent contamination of the contralateral biliary tree and associated infectious complications, though the relative effectiveness of percutaneous and endoscopic techniques is an ongoing area of study and debate. Patients with low FLR also require intervention to induce hypertrophy, most commonly portal venous embolization, in an effort to reduce the rate of postoperative liver failure. Even with extensive preoperative workup, many patients will be found to have metastatic disease at exploration and diagnostic laparoscopy may reduce the rate of non-therapeutic laparotomy. Management of perihilar cholangiocarcinoma continues to evolve, with ongoing efforts to improve preoperative liver hypertrophy and to further define the role of transplantation in disease management.

6 March 2025 in Surgery
Verified
Journal Article
Closed access
KKKristen N. Kaiser
Kristen N. Kaiser
AHAlexa J. Hughes
Alexa J. Hughes
AYAnthony D. Yang
Anthony D. Yang
SMSanjay Mohanty
Sanjay Mohanty
TMThomas K. Maatman
Thomas K. Maatman
RERyan Ellis
Ryan Ellis


31 July 2019 in BMJ Quality & Safety
Verified
Journal Article
Closed access
PDF file
RERyan Ellis
Ryan Ellis
CSCary Jo R Schlick
Cary Jo R Schlick
JFJoe Feinglass
Joe Feinglass
MMMary F Mulcahy
Mary F Mulcahy
ABAl B Benson
Al B Benson
RMRyan P Merkow
Ryan P Merkow
Background Chemotherapy quality measures consider hospitals compliant when chemotherapy is recommended, even if it is not received. This may mask shortcomings in cancer care delivery. Objectives of this study were to (1) identify patient factors associated with failure to receive recommended chemotherapy without a documented contraindication and (2) assess hospital variation in failure to administer recommended chemotherapy. Methods Patients from 2005 to 2015 with breast, colon and lung cancers who failed to receive recommended chemotherapy were identified using the National Cancer Database. Hospital-level rates of failure to administer recommended chemotherapy were calculated, and patient and hospital factors associated with failure to receive recommended chemotherapy were identified by multivariable logistic regression. Results A total of 183 148 patients at 1281 hospitals were analysed. Overall, 3.5% of patients with breast, 6.6% with colon and 10.7% with lung cancers failed to receive recommended chemotherapy. Patients were less likely to receive recommended chemotherapy in all cancers if uninsured or on Medicaid (p<0.05), as were non-Hispanic black patients with both breast and colon cancer (p<0.001). Significant hospital variation was observed, with hospital-level rates of failure to administer recommended chemotherapy as high as 21.8% in breast, 40.2% in colon and 40.0% in lung cancers. Conclusions and relevance Though overall rates are low, failure to receive recommended chemotherapy is associated with sociodemographic factors. Hospital variation in failure to administer recommended chemotherapy is masked by current quality measure definitions and may define a significant and unmeasured difference in hospital quality.

25 November 2019 in Journal of Gastrointestinal Surgery
Verified
Journal Article
Closed access
PDF file
RERyan Ellis
Ryan Ellis
LZLindsey M. Zhang
Lindsey M. Zhang
CKClifford Y. Ko
Clifford Y. Ko
MCMark E. Cohen
Mark E. Cohen
DBDavid J. Bentrem
David J. Bentrem
RMRyan P. Merkow
Ryan P. Merkow

2 October 2024 in Surgery
Verified
Journal Article
Closed access
JBJackson A. Baril
Jackson A. Baril
BRBrian M. Ruedinger
Brian M. Ruedinger
TNTrang K. Nguyen
Trang K. Nguyen
KBKarl Y. Bilimoria
Karl Y. Bilimoria
ECEugene P. Ceppa
Eugene P. Ceppa
RERyan Ellis
Ryan Ellis